



GvHGvL 2022
Regensburg, Germany
Location: University Hospital Regensburg
March 9-11, 2022

Wednesday, March 9:

13:00 Welcome

13:15 - 15:20 Session I

Pathophysiology - new aspects:

Chairs: M Edinger

13:15 - 13:40 CD162 pos macrophages and GvHD : A Beilhack, Würzburg

13:40 - 14:05 Sting/IFN signaling and microbiota: H Poeck, Regensburg

14:05 - 14:30 Role of neutrophils: R Zeiser, Freiburg

14:30 - 14:55 Tissue tolerance: P Reddy, Ann Arbor

14:55 - 15:20 IL22 and intestinal stem cells: AM Hanash, New York, virtual

15:20 - 15:45 Break

15:45 - 17:25 Session II

Biomarkers and Pathophysiology II:

Chairs: A Beilhack

15:45 - 16:10 Update on MAGIC: J Levine, New York

16:10 - 16:35 Tissue T regs: M Feuerer, LIT Regensburg (SFB)

16:35 - 17:00 T Reg repertoire: C Koenecke, Hannover

17:00 - 17:25 Interplay between endothelial damage, atherosclerosis and GvHD: A Zerneck, Würzburg

17:25 - 18:15 HJ Kolb Award and lecture 2022

18:45 - 20:15 Evening discussion

Thursday, March 10:

09:00 – 10:40 Session III

Immune Cells and immunoreconstitution

Chairs: P. Hoffmann

09:00 - 09:25 CD4 reconstitution and outcome: C. Lindemans, Utrecht

09:25 - 09:50 Enhancing thymic recovery: E Velardi, Rome

09:50 - 10:15 Tumor specific T cells in myeloma and HD: L Hansmann, Berlin

10:15 - 10:40 Peripheral antigen display and autoimmunity in GVHD: R Chakraverty, London

10:40 - 11:00 Break

11:00 - 12:15 Session IV

IgA

Chair: A Gessner

11:00 - 11:25 Intestinal IgA. Microbiota and immunoregulation: O Pabst, Aachen

11:25 - 11:50 IgA in chronic GvHD: T Winkler, Erlangen

11:50 - 12:15 Intestinal IgA pos plasma cells and GvH/GVL: E Holler, Regensburg

12:15 - 13:30 Break

13:30 - 14:20 Session V

New Treatment Options in acute GvHD

Chair: R Zeiser

13:30 - 13:55 FMT and beyond: F Malard, Paris

13:55 - 14:20 RIPK1 Inhibition and acute GvHD: JLM Ferrara, New York

14:20 - 15:10 Session VI

New Treatment Options in cGvHD

Chair: D Wolff

14:20 - 14:45 T Regs in chronic GvHD: M Edinger, Regensburg

14:45 - 15:10 Drug targetable biomarkers of chronic GvHD: S Paczesny, Indianapolis

15:10 – 15:35 Wnt signaling in cGvHD: J Distler, Erlangen

15:35 – 16:00 Break

16:00 – 16:40 Keynote lecture

Chairs: S Thomas, HJ Kolb

The role of CAR T cells in the setting of allogeneic SCT: M v d Brink, New York

16:40 – 17:00 Break

17:00 - 18:15: GvL I

Chairs: A Mackensen

17:00 - 17:25 Novel hemibodies for personalized GvL Therapy: G Stuhler

17:25 - 17:50 DP specific strategies: K Fleischhauer, Essen

17:50 - 18:15 Regulation of class II to prevent relapse: H Reimann, Erlangen

Friday, March 11:

09:00 – 10:40 GvL II

Chairs: H Einsele

09:00 - 09:25 Immune signature drives leukemia escape after aHSCT: L. Vago, Milano

09:25 - 09:50 Harnessing immune exhaustion for adoptive T cell therapy of acute myeloid leukemia: Beatrice Cianciotti, Milano

09:50 - 10:15 mutNPM1 –specific TCR in AML: Marieke Griffioen, Leiden

10:15 - 10:40 T Cell metabolism and immune escape: D Mougiakakos

10:40 – 11:00 Coffee Break

11:00 – 12:35 GvL III

Chairs: P Beckhove

11:00 - 11:25 Genome edited allo-CART: G Lucchini, London

11:25 - 11:50 Novel targets for CAR T cells in myeloma and AML: M Hudecek, Würzburg

11:50 - 12:15 CART and memory T stem cells: L Gattinoni, Regensburg

12:15 - 12:40 CAR T cell resistance: L Rasche, Würzburg

12:40 – 13:00 Closure and farewell